KSD-101

BIOLOGICAL4 trials

Sponsors

Kousai Bio Co., Ltd., Sun Yat-sen University

Conditions

EBVNasopharyngeal CarcinomaNasopharyngeal Carcinoma (NPC)Relapsed or Refractory EBV-associated Hematological Malignancies

Early Phase 1

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

RecruitingNCT06097793

Kousai Bio Co., Ltd.Nasopharyngeal Carcinoma

Start: 2023-12-04End: 2025-12-31Target: 12Updated: 2024-03-12

KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial

Not yet recruitingNCT06370026

Sun Yat-sen UniversityNasopharyngeal Carcinoma

Start: 2024-05-01End: 2026-12-31Target: 12Updated: 2024-05-02

KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Not yet recruitingNCT06752473

Kousai Bio Co., Ltd.EBV, Nasopharyngeal Carcinoma (NPC)

Start: 2025-01-31End: 2027-02-28Target: 10Updated: 2024-12-30

Phase 1

A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies

Not yet recruitingNCT07532746

Kousai Bio Co., Ltd.Relapsed or Refractory EBV-associated Hematological Malignancies

Start: 2026-05-01End: 2029-12-31Target: 55Updated: 2026-04-16